California State Teachers Retirement System Sells 156 Shares of Repligen Co. (NASDAQ:RGEN)

California State Teachers Retirement System reduced its position in shares of Repligen Co. (NASDAQ:RGEN) by 0.2% during the first quarter, Holdings Channel reports. The institutional investor owned 82,201 shares of the biotechnology company’s stock after selling 156 shares during the period. California State Teachers Retirement System’s holdings in Repligen were worth $15,118,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in RGEN. YHB Investment Advisors Inc. bought a new position in Repligen in the 1st quarter valued at about $26,000. Lazard Asset Management LLC raised its stake in shares of Repligen by 206.1% in the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 136 shares during the last quarter. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Repligen by 152.1% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 146 shares in the last quarter. Principal Securities Inc. purchased a new position in shares of Repligen during the fourth quarter valued at approximately $48,000. Finally, CWM LLC grew its holdings in Repligen by 19.9% during the first quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock worth $66,000 after buying an additional 60 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

RGEN has been the topic of a number of analyst reports. Guggenheim initiated coverage on shares of Repligen in a report on Tuesday, June 18th. They set a “neutral” rating on the stock. JPMorgan Chase & Co. boosted their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Wednesday. UBS Group decreased their price objective on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday. Deutsche Bank Aktiengesellschaft upgraded Repligen from a “hold” rating to a “buy” rating and cut their target price for the stock from $180.00 to $155.00 in a research note on Wednesday, June 26th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $190.00 price target on shares of Repligen in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $190.88.

Repligen Stock Performance

Shares of RGEN opened at $155.13 on Friday. Repligen Co. has a 1 year low of $110.45 and a 1 year high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.35 and a quick ratio of 5.24. The stock’s fifty day moving average price is $134.85 and its two-hundred day moving average price is $166.13. The firm has a market cap of $8.69 billion, a PE ratio of 662.71, a PEG ratio of 5.65 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The business had revenue of $154.07 million for the quarter, compared to the consensus estimate of $154.11 million. During the same period in the prior year, the firm earned $0.53 earnings per share. The company’s revenue was down 3.2% compared to the same quarter last year. On average, equities research analysts forecast that Repligen Co. will post 1.44 EPS for the current year.

Insiders Place Their Bets

In related news, VP Ralf Kuriyel sold 4,465 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the sale, the vice president now owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Repligen news, CEO Anthony Hunt sold 20,072 shares of the firm’s stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total value of $3,377,314.72. Following the sale, the chief executive officer now owns 163,177 shares of the company’s stock, valued at approximately $27,456,162.02. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Ralf Kuriyel sold 4,465 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the transaction, the vice president now directly owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The disclosure for this sale can be found here. Company insiders own 1.20% of the company’s stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.